It is well established that human and animal skin harbours commensal bacteria that generally live on the skin without causing harm. Certain bacteria colonizing healthy skin produce molecules which effectively kill pathogens that cause infections in humans and animals. It was recently reported that patients with diseased skin, such as those with atopy, demonstrate a different array of bacterial species in their commensal skin microbiome compared to patients with healthy skin. Not only is the microbiome of healthy skin qualitatively different to atopic skin in the array of bacterial species present, but functional differences exist between the microbiome of healthy and diseased skin. Bacterial production of antimicrobial molecules is deficient in atopic patients compared to healthy individuals, which may be one reasons why atopic patients are predisposed to S. aureus infections.
Researchers at UC San Diego have come up with a method to use the bacterium S. felis C4 to treat diseased skin of dogs, cats and dairy cows to outcompete and kill pathogenic bacteria that are causing infections such as bacterial pyoderma and mastitis. S. felis C4 is a non-pathogenic strain of bacteria that kills several other strains of bacteria but not healthy commensal bacteria. S. felis C4 does this by producing an antimicrobial peptide which targets other bacteria and causes their death. Killing of pathogenic bacteria in diseased skin will result in resolution of the infection. The structure of the purified antimicrobial peptide from S. felis can be synthesized through information gathered by the genome sequence and protein structural data. This synthesized protein may be used as a topical antimicrobial treatment of skin infections in dogs, cats and dairy cows, or the live S. felis C4 can be used as a probiotic for topical application.
Topical probiotic, synthetic peptides or bacterial extract to be used for the treatment of bacterial skin infection and skin dysbiosis in animals, topical antimicrobial to be used as a skin infection in animals, topical antimicrobial for humans.
The concept of microbial skin transplant as a topical probiotic in animals has not been reported in scientific literature and is therefore a novel concept in veterinary medicine. Similarly, S. felis has not previously been demonstrated to outcompete other bacteria, nor to produce antimicrobial peptides, so this is a novel development in the field.
The invention is currently in experimental stage.
This technology is patent pending and available for licensing.
Therapeutics, antimicrobials, antibiotics, probiotics, microbiome, S. aureus, S. felis